Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | THADA |
| Gene Name: | THADA |
| Protein Full Name: | Thyroid adenoma-associated protein |
| Alias: | Death receptor-interacting; FLJ21877; GITA; KIAA1767; Thyroid adenoma associated |
| Mass (Da): | 219607 |
| Number AA: | 1953 |
| UniProt ID: | Q6YHU6 |
| Locus ID: | 63892 |
| COSMIC ID: | THADA |
| Gene location on chromosome: | 2p21 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19717 |
| Percent of cancer specimens with mutations: | 0.98 |
| Deregulated in translocations: | Chromosomal aberrations involving THADA have been observed in benign thyroid adenomas. Translocation t(2;3)(p21;p25) and translocation t(2;7)(p21;p15); the sequences derived from chromosomes 3p25 and 7p15 do not appear to include a coding region and the f |
| Normal role description: | THADA is expressed in pancreas, adrenal medulla, thyroid, adrenal cortex, testis, thymus, small intestine and stomach. In thyroid adenoma, translocations usually result in nonfunctional protein. THADA normally binds to death-receptor 5 (DR5) and is therefore involved in TRAIL-associated apoptosis. Presumably, loss of function in thyroid adenomas leads to disregulated cell survival. |